GlassScriptPhysician profile
Katherine M Sumner
NPI 1033500988
$3,394.94
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,727 · 2022: $1,341 · 2023: $161 · 2024: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $514.99 | 2021-2023 | Descovy |
| Genentech USA, INC. | $412.43 | 2021 | |
| Abbvie INC. | $301.53 | 2021-2022 | |
| Horizon Therapeutics Plc | $238.97 | 2021 | |
| Edwards Lifesciences Corporation | $236.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.10 | 2021-2022 | |
| Novo Nordisk INC | $194.79 | 2022-2024 | |
| Abbott Laboratories | $144.61 | 2022-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2022 | |
| Mayne Pharma Commercial LLC | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $120.35 | 2021 | |
| Idorsia Pharmaceuticals US INC | $114.51 | 2022 | |
| Neurocrine Biosciences, INC. | $111.88 | 2021 | |
| Solventum Corporation | $96.46 | 2024 | Promogran Prisma, Activ.A.C. |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93.50 | 2022 | |
| Csl Behring | $88.70 | 2022 | |
| Celgene Corporation | $78.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.20 | 2021 | |
| Dexcom, INC. | $12.81 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.